Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Maravai LifeSciences refinanced its credit agreement, establishing a $150 million term loan and a $30 million revolving credit facility. The company used the new term loan plus $98.5 million in cash to prepay its prior debt, reducing total principal from $242.9 million to $150 million.
Key figures
- New debt principal
- 150000000
- Term loan facility
- 150000000
- Prior debt principal
- 242900000
- Cash used for prepayment
- 98500000
- Revolving credit facility
- 30000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.